×
Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-11-04

Jul 19th, 2018 - Background: Predicting patient-specific clinical response to anticancer therapy is the holy grail of treatment-selection. It is now clear that response or resistance to therapy depends on the heterogeneous tumor microenvironment, which is comprised of malignant cells, normal stroma, soluble ligands, and tumor-immune contexture; attributes that are unique to each individual patient. This is part...

Again, a PARP Inhibitor Has Potential in BRCA+ Breast Cancer
http://www.medscape.com/viewarticle/889875

Dec 11th, 2017 - A second PARP inhibitor shows promise in germline mutation metastatic breast cancer and is generally well tolerated compared with standard chemotherapy.

Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?
http://www.ascopost.com/issues/february-10-2018/adjuvant-zoledronic-acid-in-early-breast-cancer-is-5-years-better/

Feb 10th, 2018 - THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.

Abstract P4-08-05: Impact of common polymorphisms of CYP19A1 and UGT2B17 gene deletion on early endocrine-responsive postmenopausal breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-05

Jul 23rd, 2018 - Background Polymorphisms of genes involved in estrogen production have been linked to breast cancer risk, prognosis and treatment response. Polymorphisms of the aromatase gene CYP19A1 influence its activity. The UGT2B17 catalyzes glucuronic acid transfer to a variety of substrates, including steroids and drugs like the aromatase inhibitor exemestane. We investigated the impact of two variants o...

Axillary Node Management for Breast Cancer: Is Less More?
https://www.cancertherapyadvisor.com/breast-cancer/breast-cancer-axillary-node-management-treatment/article/713742/

Dec 12th, 2017 - Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings.

Breast Pain Uncommon Symptom of Breast Cancer
http://www.medscape.com/viewarticle/890247

Dec 18th, 2017 - Breast pain is not often a symptom of breast cancer regardless of age, and mostly women need to be reassured that breast pain is both common and benign.

Abstract P1-06-12: Optimizing the use of oncotype Dx in early breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-12

Jul 31st, 2018 - Background: Oncotype Dx (ODX) prognosticates the risk of recurrence and predicts the benefit of adjuvant chemotherapy in estrogen-receptor-positive breast cancer (BC). However, its cost makes it prohibitive for many health care systems. Our objective was to develop a model that uses routine clinical and pathological parameters to identify ODX high risk patients which require adjuvant chemothera...

CDK 4/6 Inhibitors May Be Effective but More Toxic in Older Women
http://www.ascopost.com/issues/february-10-2018/cdk-46-inhibitors-may-be-effective-but-more-toxic-in-older-women/

Feb 10th, 2018 - OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or older enrolled in registration trials of these agents.

CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer
https://www.onclive.com/conference-coverage/sabcs-2017/cdk46-improved-pfs-in-older-women-with-hr-metastatic-breast-cancer-

Dec 8th, 2017 - Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival  benefit similar to that seen in their younger counterparts

Abstract P1-06-07: Mayo clinic TNBC outcome calculator: A clinical calculator to predict disease relapse and survival in women with triple-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-07

Aug 4th, 2018 - Purpose: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with substantial risks of disease recurrence. While cytotoxic chemotherapy is commonly administered and reduces recurrence, disease outcomes vary considerably and few prognostic tools are available for risk stratification for TNBC patients. We constructed and validated clinical calculators for invasive-disease ...

Abstract P1-06-10: Correlative analysis of breast cancer index (BCI) restratification of 21-gene recurrence score (RS) in patients with hormone receptor-positive (HR+), node-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-10

Aug 5th, 2018 - Background: In a cross-stratification analysis performed within the TransATAC cohort, Breast Cancer Index (BCI) and 21-gene Recurrence Score (RS) had a concordance of 58.2% (Sestak et al., Clin Cancer Res, 2016). Restratification by BCI of the low and intermediate RS risk groups led to subgroups with significantly different rates (P < 0.001 and P = 0.003, respectively); in contrast, restratifie...

Abstract P3-08-08: Prognostic associations of plasma hepcidin in early breast cancer (BC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-08

Aug 15th, 2018 - Background: Intra-tumor RNA expression of hepcidin has been linked to adverse metastasis-free survival in women with early BC, but the prognostic implications of this inflammatory marker and iron-regulating peptide are unknown. Methods: Using an ELISA assay, we measured plasma hepcidin in the banked blood of 518 women who were recruited from 1989-1996 for a prospective cohort study regarding di...

Abstract P3-08-13: Serum thymidine kinase activity is an independent prognostic factor for progression-free and overall survival in women with metastatic breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-13

Aug 21st, 2018 - Introduction: Although prognosis and treatment of metastatic breast cancer (MBC) have improved over the last years, there is still an unmet clinical need for more precise prognostic and treatment monitoring tools. Liquid-based markers are preferred since they reflect real-time tumor progression and are not dependent on repeated invasive tissue biopsies. Thymidine kinase 1 (TK1) is an enzyme inv...

Dosing Modifications Shown to Improve Outcomes In Breast Cancer
https://www.targetedonc.com/conference/2017-sabcs/dosing-modifications-shown-to-improve-outcomes-in-breast-cancer

Dec 6th, 2017 - Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.

Enzalutamide plus exemestane improves PFS in HR+ breast cancer subset
https://www.mdedge.com/oncologypractice/article/155272/breast-cancer/enzalutamide-plus-exemestane-improves-pfs-hr-breast

Jan 2nd, 2018 - Enzalutamide added to exemestane improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer, investigators reported

ERBB2 expression predicts pCR in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155137/breast-cancer/erbb2-expression-predicts-pcr-her2-breast-cancer

Dec 26th, 2017 - Among patients receiving trastuzumab plus lapatinib neoadjuvant therapy for HER2-positive early breast cancer, amplification of ERBB2 was predictive of a pathologic complete response (pCR), according to findings presented at the San Antonio Breast Cancer Symposium.

Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-report...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-01

Aug 24th, 2018 - Background: SOLE efficacy results presented at ASCO 2017 showed that extended intermittent vs continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women who had received 4-6 years of adjuvant endocrine therapy for hormone-receptor positive (HR+), lymph-node positive breast cancer. Previous studies showed that the burden by symptoms related to endocrine therap...

Exemestane plus enzalutamide extends PFS in some women with breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B99e9af8c-7703-431e-ab0d-71b296bb9b5b%7D/exemestane-plus-enzalutamide-extends-pfs-in-some-women-with-breast-cancer

Dec 8th, 2017 - The addition of enzalutamide to exemestane significantly prolonged PFS and appeared well tolerated among patients with hormone receptor-positive metastatic breast cancer who had not received prior endocrine therapy and who expressed an androgen receptor gene signature, according to results of a placebo-controlled randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.

Extended Endocrine Therapy in Postmenopausal Women With Breast Cancer: 2 Years as Effective as 5 Years
http://www.ascopost.com/issues/december-25-2017/extended-endocrine-therapy-in-postmenopausal-women-with-breast-cancer-2-years-as-effective-as-5-years/

Dec 25th, 2017 - An additional 5 years of aromatase inhibitor therapy after 5 years of adjuvant endocrine therapy failed to improve disease-free survival compared with an additional 2 years of aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive breast cancer, according to the results of the large Austrian Breast and Colorectal Cancer Study Group (ABCSG)-16 trial presented at the 2...

Abstract P5-18-04: Bridging gaps in breast cancer care: A pilot forum for mental health professionals
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-04

Aug 26th, 2018 - Introduction: Supporting the emotional needs of women diagnosed with breast cancer is a recognized priority for cancer clinicians and a core component of high quality care and survivorship programs. We hypothesized that mental health professionals would benefit from an educational program directed to enhance their practical knowledge of breast cancer. Methods: We designed an innovative educatio...

Fulvestrant + Anastrozole Improves Long-Term PFS and OS vs Anastrozole Alone in Women With Postmenopausal Metastatic Breast Cancer
https://www.practiceupdate.com/content/sabcs-2017nbspfulvestrant-anastrozole-improves-long-term-pfs-and-os-vs-anastrozole-alone-in-women-with-postmenopausal-metastatic-breast-cancer/61146/62

Dec 8th, 2017 - Fulvestrant + anastrozole has been shown to improve long-term progression-free and overall survival vs anastrozole alone in women with postmenopausal metastatic breast cancer, despite the use of fulvestrant at a lower dose than approved, and despite substantial crossover to fulvestrant after progression with anastrozole alone.

Abstract P6-11-02: Voice of cancer patients: Analysis of patient concerns regarding scalp cooling devices for prevention of chemotherapy induced alopecia
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-02

Aug 28th, 2018 - Adjuvant chemotherapies for breast cancer cause hair loss in majority of patients. Although Chemo Induced Alopecia (CIA) is temporary, is distressing for many patients and about 7% patients treated with docetaxel experience permanent hair loss. Scalp cooling devices (SCDs) have been shown to reduce hair loss in patients receiving chemo. Many patients share their experiences in online forums as ...

Abstract P6-11-06: Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients: A retrospective, comprehensive review of 330 cases of Brazil
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-06

Aug 29th, 2018 - Background: Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of many chemotherapy (CT) agents. New strategies for prevention of CIA have been studied. Scalp cooling has been reported to prevent CIA. We conducted a retrospective study aimed to assess the efficacy of scalp cooling in preventing CIA among women receiveing chemotherapy for breast cancer. Methods: Was included cli...

Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide
https://www.onclive.com/conference-coverage/sabcs-2017/genebased-biomarker-identifies-patients-with-breast-cancer-more-likely-to-respond-to-enzalutamide

Dec 8th, 2017 - Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

Lapatinib plus trastuzumab improves outcomes in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155150/breast-cancer/lapatinib-plus-trastuzumab-improves-outcomes-her2

Dec 27th, 2017 - Results from CALGB 40601 conflict with those from two larger trials that failed to find a benefit for dual HER2 blockade in treating HER2+ breast cancer.

High rate of arm morbidity in young breast cancer survivors
https://www.mdedge.com/oncologypractice/article/154705/breast-cancer/high-rate-arm-morbidity-young-breast-cancer-survivors

Dec 18th, 2017 - Undergoing axillary lymph node dissection (ALND) is more likely to result in arm swelling and decreased range of arm motion in young breast cancer patients, as compared with having a sentinel lymph node biopsy (SLNB), according to new findings.

Modest Weight Loss Cuts Postmenopausal Breast Cancer Risk
http://www.medscape.com/viewarticle/889854

Dec 11th, 2017 - Women who lose just 5% of their body weight after the menopause may experience a significant reduction in their risk of developing breast cancer vs women with stable weight, say US researchers.

Abstract P6-11-08: Chemotherapy-induced peripheral neuropathy and quality of life among breast cancer survivors
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-08

Aug 30th, 2018 - Introduction: Breast cancer survivors are at risk for long-term chemotherapy-induced peripheral neuropathy (PN), which has few treatment options and can affect quality of life. We examined 1) the presence and severity of PN and its correlates among 442 metastatic (MBC) and 238 breast cancer (BC) survivors who received chemotherapy, and 2) provider communication, preparation, and confidence in m...

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer
https://www.cancertherapyadvisor.com/breast-cancer/abemaciclib-benefit-breast-cancer-poor-prognostic-markers-risk/article/713426/

Dec 11th, 2017 - This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer
https://ecancer.org/conference/966-sabcs-2017/news/12915-sabcs-2017--phase-iii-trial-data-supports-current-standard-12-month-adjuvant-trastuzumab-for-her2-positive-breast-cancer.php

Dec 7th, 2017 - Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, ...

Abstract P6-11-14: Safety and effectiveness of sensor-controlled scalp cooling to prevent alopecia in primary breast cancer patients receiving neoadjuvant or adjuvant epirubicin, taxanes, or both
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-14

Sep 9th, 2018 - Background: Chemotherapy (Ctx)-induced alopecia (CIA), produces a deep psychological distress in many women involved. Sensor-controlled scalp cooling (SCSC) is now approved by the FDA due to both its effectiveness and safety to prevent CIA demonstrated in two randomized trials in patients (pts) with primary breast cancer (PBC). However, SCSC is still infrequently used in many countries due to p...

Ribociclib Doubles Progression-Free Survival in Premenopausal Breast Cancer
http://www.ascopost.com/issues/december-25-2017/ribociclib-doubles-progression-free-survival-in-premenopausal-breast-cancer/

Dec 25th, 2017 - PREMENOPAUSAL WOMEN with hormone receptor–positive, HER2-negative advanced breast cancer benefited substantially from the addition of ribociclib (Kisqali) to first-line endocrine therapy plus medical ovarian suppression, according to results from the MONALEESA-7 study.

Researchers quantify presence of immunotherapy biomarkers in breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B4ee9505a-d5b1-4da3-b899-d6c77ebc5a22%7D/researchers-quantify-presence-of-immunotherapy-biomarkers-in-breast-cancer

Dec 8th, 2017 - Although a minority of patients with invasive breast cancer expressed microsatellite instability, high tumor mutational load or PD-L1 expression, these biomarkers may elucidate the benefit of immune checkpoint inhibitors for the disease, according to results of a retrospective data analysis presented at the San Antonio Breast Cancer Symposium.

Abstract P5-22-07: Upgrade to high risk lesions, in situ and invasive cancer among women with benign papillary lesions diagnosed on image-guided core needle biopsy (IGCNB)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-07

Dec 15th, 2018 - Background: Currently there is no consensus regarding the management of benign papillary breast lesions diagnosed on IGCNB. Recommendations vary as to whether all IGCNB papillary lesions require surgical excision or if IGCNB alone is adequate to confirm a benign diagnosis and patients can be followed with imaging. Aims: To estimate percentage of patients with benign papilloma on IGNB who on sur...

Ribociclib Improves PFS by 10.8 Months in HR+/HER2- Premenopausal Breast Cancer
https://www.onclive.com/conference-coverage/sabcs-2017/ribociclib-improves-pfs-by-108-months-in-hrher2-premenopausal-breast-cancer

Dec 6th, 2017 - Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-22

Dec 16th, 2018 - Introduction: Close to 65% of BRCA mutation carriers do not choose prophylactic mastectomy, despite their high breast cancer risk. Breast reduction mammoplasty is a surgical technique shown to reduce breast cancer risk and can be modified to target specific areas of the breast. We wondered if a majority of tumors in BRCA mutation carriers would be confined to one quadrant, allowing for the use ...

Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-18

Sep 12th, 2018 - Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is essential to preserve quality of life in cancer patients receiving highly emetogenic chemotherapy (HEC) such as doxorubicin-cyclophosphamide (AC) or cisplatin. Recently, new drugs (e.g. fosaprepitant and newer neurokinin 1 receptor antagonists [NK1RAs], rolapitant and netupitant) and updated guidelines for antiemetic use ...

Abstract P5-22-20: Oncologic safety of endoscopic assisted breast surgery compared with conventional breast surgery: An analysis of 1295 primary operable breast cancer patients from single institute
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-20

Dec 17th, 2018 - Background:Endoscopy-assisted breast surgery (EABS) performed through minimal axillary and/or periareolar incisions is a possible alternative to open surgery for certain patients with breast cancer. In this study, we report the oncologic safety results of EABS compared with conventional breast surgery (CBS). Methods: The medical records of patients who underwent EABS for breast cancer during th...

Statins May Up Breast Cancer-Specific and Overall Survival
http://www.medscape.com/viewarticle/889813

Dec 8th, 2017 - Statins may improve breast cancer outcomes whether women take them before or after their diagnosis and extend overall survival as well.

Abstract P5-22-23: Electrochemotherapy : A new local therapy for cutaneous metastases of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-23

Dec 18th, 2018 - Background : Electrochemotherapy (ECT) is a new local therapy combining the administration of an intravenous chemotherapy (bleomycin) followed by the direct application of electric pulses by an electrode to the treated areas. Electric pulses transiently permeabilize the membrane of the tumor cell ( electroporation), improving intracellular diffusion of a poorly permeant chemotherapeutic agent, ...

Talazoparib improves PFS over chemotherapy for patients with BRCA mutations
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7Ba100040a-b819-4546-8436-fe6f5a5d16f6%7D/talazoparib-improves-pfs-over-chemotherapy-for-patients-with-brca-mutations

Dec 14th, 2017 - The PARP inhibitor talazoparib improved PFS over investigator’s choice chemotherapy among patients with advanced breast cancer and a BRCA germline mutation, according to results of the phase 3 EMBRACA study presented at the San Antonio Breast Cancer Symposium.

Temporary ovarian suppression preserves fertility during chemotherapy
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B275c318a-d8ca-46af-ac78-2c2db173d8ff%7D/temporary-ovarian-suppression-preserves-fertility-during-chemotherapy

Dec 7th, 2017 - Women treated with gonadotropin-releasing hormone agonists during treatment with chemotherapy for premenopausal early breast cancer experienced a significant reduction in the risk for chemotherapy-induced premature ovarian insufficiency, according to data from a systemic review and meta-analysis presented at the San Antonio Breast Cancer Symposium.

Abstract P5-22-04: Efficacy of thoracic paravertebral block for reducing acute post-mastectomy pain
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-04

Dec 19th, 2018 - Background: Mastectomy is associated with acute and chronic postoperative pain. This study investigated the efficacy of thoracic paravertebral block (TPB) compared to local anesthetic of surgical wound (LASW) in breast cancer patients undergoing mastectomy. Methods: This phase 3, randomized controlled, single blind, parallel arms and superiority clinical trial aimed to evaluate the efficacy of ...

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers
https://www.onclive.com/conference-coverage/sabcs-2017/trastuzumab-deruxtecan-impresses-in-her2-expressing-breast-cancers

Dec 8th, 2017 - Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

Trastuzumab Disappoints in HER2-low Patient Cohort
https://www.onclive.com/conference-coverage/sabcs-2017/trastuzumab-disappoints-in-her2low-patient-cohort

Dec 6th, 2017 - A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

Abstract P6-13-04: IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-13-04

Sep 16th, 2018 - Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with histologically proven invasive stage I-II, hormone receptor (HR) positive, and HER2-negative breast cancer. Methods: The study included 369 women from 1...

Abstract P5-22-10: Intraoperative ultrasound guided surgery after neoadjuvant treatment in breast cancer improves patient´s quality of life
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-10

Dec 21st, 2018 - Background: Intraoperative ultrasound guided surgery (IOUS) has shown not only to improve surgical outcomes by achieving higher rates of negative margins and reducing the need for re-excisions, but also showing better cosmetic results and patient's satisfaction in the adjuvant setting. After neoadjuvant treatments (NAT) we have shown that IOUS lowers the volume of resection in patients with pat...

Wider margins may reduce recurrence risk in early breast cancer
https://www.mdedge.com/oncologypractice/article/155336/breast-cancer/wider-margins-may-reduce-recurrence-risk-early-breast

Jan 2nd, 2018 - A margin width beyond ‘no tumor on ink’ may reduce local recurrence in certain subsets of patients undergoing breast-conserving treatment for early-stage breast cancer, according to findings from a meta-analysis.

Abstract P6-13-03: Breast cancer-specific mortality (BCSM) in patients with node-positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-13-03

Sep 18th, 2018 - Introduction: The Recurrence Score® (RS) assay was shown in SWOG 8814 to predict chemotherapy (CT) benefit for patients (pts) with N+ BC and RS ≥31 but not RS <18. As we await the randomized RxPONDER results for RS 0-25, we characterized BCSM for RS groups (cutoffs of 11, 18, 25, and 31) in the large population-based SEER study of pts treated based on RS results. Methods: RS results were provid...

Abstract P5-22-19: Nipple sparing mastectomy in unselect patients: Experience of an academic center in the south of Brazil
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-19

Dec 22nd, 2018 - INTRODUCTION: Nipple sparing mastectomy (NSM) consists in the complete excision of the breast gland, mantaining the subcutaneous tissue, skin and nipple-areola complex (NAC). Recently, the NSM was developed as a therapeutic option not just for the patients that need risk-reducing surgery, but also for patients that have tumors not involving the NAC. OBJECTIVES: Evaluate the overall survival, di...